Published in PLoS Med on March 08, 2011
Source memory in the rat. Curr Biol (2013) 1.86
Through the fog: recent clinical trials to preserve β-cell function in type 1 diabetes. Diabetes (2012) 1.07
Efficacy and safety of mesenchymal stromal cells in preclinical models of acute lung injury: a systematic review protocol. Syst Rev (2014) 0.91
Assessing risk/benefit for trials using preclinical evidence: a proposal. J Med Ethics (2015) 0.90
A biological perspective on memory. Curr Biol (2013) 0.88
Recommendations for nanomedicine human subjects research oversight: an evolutionary approach for an emerging field. J Law Med Ethics (2012) 0.87
Building an ethical foundation for first-in-human nanotrials. J Law Med Ethics (2012) 0.84
Beyond bench and bedside: disentangling the concept of translational research. Health Care Anal (2015) 0.84
Stem cell trials for cardiovascular medicine: ethical rationale. Tissue Eng Part A (2013) 0.79
Perspective: Rethink the immune connection. Nature (2012) 0.77
How can institutional review boards best interpret preclinical data? PLoS Med (2011) 0.76
Ethics, error, and initial trials of efficacy. Sci Transl Med (2013) 0.75
Barriers to developing a valid rodent model of Alzheimer's disease: from behavioral analysis to etiological mechanisms. Front Neurosci (2015) 0.75
Stakeholder views on participant selection for first-in-human trials in cancer nanomedicine. Curr Oncol (2016) 0.75
How to keep high-risk studies ethical: classifying candidate solutions. J Med Ethics (2016) 0.75
Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol (2010) 27.58
Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov (2004) 15.57
Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med (2001) 9.51
Survey of the quality of experimental design, statistical analysis and reporting of research using animals. PLoS One (2009) 7.60
Can animal models of disease reliably inform human studies? PLoS Med (2010) 6.27
A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol (2003) 6.21
ICH harmonized tripartite guideline: Guideline for Good Clinical Practice. J Postgrad Med (2001) 6.16
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology (2009) 5.94
Publication bias in reports of animal stroke studies leads to major overstatement of efficacy. PLoS Biol (2010) 5.58
Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology (2005) 5.51
Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol (2006) 5.49
Alzheimer's disease: clinical trials and drug development. Lancet Neurol (2010) 4.65
Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA (2009) 4.02
Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol (2010) 3.84
Translation of highly promising basic science research into clinical applications. Am J Med (2003) 3.74
Stem cells in human neurodegenerative disorders--time for clinical translation? J Clin Invest (2010) 3.62
Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology (2010) 3.58
Good laboratory practice: preventing introduction of bias at the bench. Stroke (2008) 3.27
Treatment success in cancer: new cancer treatment successes identified in phase 3 randomized controlled trials conducted by the National Cancer Institute-sponsored cooperative oncology groups, 1955 to 2006. Arch Intern Med (2008) 3.07
Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology (2003) 2.65
The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology (2009) 2.62
Methodological quality of animal studies of neuroprotective agents currently in phase II/III acute ischemic stroke trials. Stroke (2008) 2.58
Evaluation of new treatments in radiation oncology: are they better than standard treatments? JAMA (2005) 2.37
Drug development for CNS disorders: strategies for balancing risk and reducing attrition. Nat Rev Drug Discov (2007) 1.91
Alzheimer's failure raises questions about disease-modifying strategies. Nat Rev Drug Discov (2010) 1.64
Effects of NXY-059 in experimental stroke: an individual animal meta-analysis. Br J Pharmacol (2009) 1.60
Neuroscience. Fetal cells again? Science (2009) 1.54
Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study. Dement Geriatr Cogn Disord (2010) 1.45
Does random treatment assignment cause harm to research participants? PLoS Med (2006) 1.39
Research ethics. Beyond access vs. protection in trials of innovative therapies. Science (2010) 1.23
The need to consider the wider agenda in systematic reviews and meta-analyses: breadth, timing, and depth of the evidence. BMJ (2010) 1.20
Launching invasive, first-in-human trials against Parkinson's disease: ethical considerations. Mov Disord (2009) 1.18
What can be inferred from the interruption of the semagacestat trial for treatment of Alzheimer's disease? Biol Psychiatry (2010) 1.11
Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease. Expert Opin Pharmacother (2009) 1.07
Drug administration in animal studies of cardiac arrest does not reflect human clinical experience. Resuscitation (2007) 1.00
Critical role of phase I clinical trials in cancer treatment. American Society of Clinical Oncology. J Clin Oncol (1997) 0.98
Extending clinical equipoise to phase 1 trials involving patients: unresolved problems. Kennedy Inst Ethics J (2010) 0.94
A call for physiopathological ethics. Mol Ther (2008) 0.92
Phenserine efficacy in Alzheimer's disease. J Alzheimers Dis (2010) 0.92
The ethics of advertising for health care services. Am J Bioeth (2014) 6.87
Research at the auction block: Problems for the fair benefits approach to international research. Hastings Cent Rep (2010) 1.78
The structure of clinical translation: efficiency, information, and ethics. Hastings Cent Rep (2015) 1.46
Launching invasive, first-in-human trials against Parkinson's disease: ethical considerations. Mov Disord (2009) 1.18
Ethical considerations in the conduct of electronic surveillance research. J Law Med Ethics (2006) 0.92
Reviewing HIV-Related Research in Emerging Economies: The Role of Government Reviewing Agencies. Dev World Bioeth (2014) 0.83
Equipoise in the enhanced supression of the platelet IIb/IIIa receptor with integrilin trial (ESPRIT): a critical appraisal. Clin Trials (2005) 0.78
Equipoise and the criteria for reasonable action. J Law Med Ethics (2006) 0.77
Response to open peer commentaries on "The ethics of advertising for health care services". Am J Bioeth (2014) 0.75
Incidental findings in the use of DNA to identify human remains: an ethical assessment. Forensic Sci Int Genet (2012) 0.75
The Pluralism of Coherent Approaches to Global Health. Hastings Cent Rep (2017) 0.75
Learning health systems, clinical equipoise and the ethics of response adaptive randomisation. J Med Ethics (2017) 0.75
The community speaks: understanding ethical values in allocation of scarce lifesaving resources during disasters. Ann Am Thorac Soc (2014) 0.75